BR0111852A - Nova interferona para o tratamento de esclerose múltipla - Google Patents

Nova interferona para o tratamento de esclerose múltipla

Info

Publication number
BR0111852A
BR0111852A BR0111852-8A BR0111852A BR0111852A BR 0111852 A BR0111852 A BR 0111852A BR 0111852 A BR0111852 A BR 0111852A BR 0111852 A BR0111852 A BR 0111852A
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
treatment
ifn
humans
biologically active
Prior art date
Application number
BR0111852-8A
Other languages
English (en)
Inventor
Edward M Croze
Daryl Faulds
T Charis Wagner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0111852A publication Critical patent/BR0111852A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"NOVA INTERFERONA PARA O TRATAMENTO DE ESCLEROSE MúLTIPLA". A presente invenção se refere a novos ácidos nucléicos e seq³ências de polipeptídeos, que codificam uma interferona-beta-2 ("IFN-<225>2"). Uma composição farmacêutica, que compreende um excipiente farmaceuticamente aceitável e uma proporção terapeuticamente eficiente de um polipeptídeo de IFN-<225>2, um de seus fragmentos biologicamente ativos, ou um de seus derivados biologicamente ativos, é útil no tratamento da esclerose múltipla em seres humanos.
BR0111852-8A 2000-06-16 2001-06-18 Nova interferona para o tratamento de esclerose múltipla BR0111852A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21204600P 2000-06-16 2000-06-16
US09/881,050 US20020025304A1 (en) 2000-06-16 2001-06-15 Novel interferon for the treatment of multiple sclerosis
PCT/US2001/041022 WO2001095929A2 (en) 2000-06-16 2001-06-18 Interferon for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
BR0111852A true BR0111852A (pt) 2003-05-20

Family

ID=26906704

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111852-8A BR0111852A (pt) 2000-06-16 2001-06-18 Nova interferona para o tratamento de esclerose múltipla

Country Status (22)

Country Link
US (1) US20020025304A1 (pt)
EP (1) EP1289541A2 (pt)
JP (1) JP2004505021A (pt)
KR (1) KR20030009529A (pt)
CN (1) CN1436086A (pt)
AU (1) AU2001267099A1 (pt)
BG (1) BG107370A (pt)
BR (1) BR0111852A (pt)
CA (1) CA2413077A1 (pt)
CZ (1) CZ20024094A3 (pt)
EE (1) EE200200693A (pt)
HU (1) HUP0300787A2 (pt)
IL (1) IL152996A0 (pt)
LT (1) LT2002123A (pt)
MX (1) MXPA02012308A (pt)
NO (1) NO20025964L (pt)
NZ (1) NZ522849A (pt)
PL (1) PL359562A1 (pt)
RU (1) RU2003100517A (pt)
SI (1) SI21080A (pt)
SK (1) SK17612002A3 (pt)
WO (1) WO2001095929A2 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1565205A4 (en) * 2002-11-18 2006-07-05 Maxygen Inc INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES
EP1712992A1 (en) * 2005-04-11 2006-10-18 Sony Ericsson Mobile Communications AB Updating of data instructions
WO2011103164A1 (en) * 2010-02-18 2011-08-25 Centocor Ortho Biotech Inc. Monkey homolog of human interferon omega
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
WO2018144999A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
WO2018141964A1 (en) 2017-02-06 2018-08-09 Orionis Biosciences Nv Targeted chimeric proteins and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
CZ329596A3 (en) * 1994-05-10 1997-05-14 Immulogic Pharma Corp Preparation for treating scattered sclerosis
CA2311681A1 (en) * 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon
EP1082132A1 (en) * 1998-05-29 2001-03-14 Biogen, Inc. Recombinant human interferon beta-1a (ifn-beta-1a) formulation
IL142061A0 (en) * 1998-09-18 2002-03-10 Zymogenetics Inc Interferon-epsilon
AU2001255380A1 (en) * 2000-04-14 2001-10-30 Zymogenetics Inc. Human interferon, zinf2

Also Published As

Publication number Publication date
BG107370A (en) 2003-11-28
NO20025964D0 (no) 2002-12-12
EE200200693A (et) 2004-06-15
RU2003100517A (ru) 2004-06-27
MXPA02012308A (es) 2003-04-25
AU2001267099A1 (en) 2001-12-24
PL359562A1 (en) 2004-08-23
KR20030009529A (ko) 2003-01-29
CA2413077A1 (en) 2001-12-20
HUP0300787A2 (hu) 2003-07-28
US20020025304A1 (en) 2002-02-28
LT2002123A (en) 2003-06-25
IL152996A0 (en) 2003-06-24
CZ20024094A3 (cs) 2003-05-14
JP2004505021A (ja) 2004-02-19
SK17612002A3 (sk) 2003-08-05
NO20025964L (no) 2003-02-14
WO2001095929A2 (en) 2001-12-20
WO2001095929A3 (en) 2002-10-10
EP1289541A2 (en) 2003-03-12
CN1436086A (zh) 2003-08-13
NZ522849A (en) 2004-05-28
SI21080A (sl) 2003-06-30

Similar Documents

Publication Publication Date Title
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
BG101118A (en) Therapeutical compounds
HK184896A (en) Pharmaceutical composition comprising loratadine ibuprofen and pseudoephedrine
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
IL138665A0 (en) Peptide factor
HK1003978A1 (en) Composition for the treatment of schizophrenia
YU83502A (sh) Nova farmaceutska smeša
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
BR9909958A (pt) Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos
BR9814498A (pt) Processo para o tratamento de obesidade em um humano necessitando de tal tratamento, composto, uso do mesmo, produto, e, composição farmacêutica
DE69429365D1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
BR0214075A (pt) Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação
BR0111852A (pt) Nova interferona para o tratamento de esclerose múltipla
KR970703353A (ko) 단핵구 주화성 단백질-4(monocyte chemotactic protein-4)
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
CA2334941A1 (en) Tnf-derived peptides for use in treating oedema
PT817646E (pt) Metodos de tratamento da inflamacao e formulacoes para esse fim
DE69334068D1 (de) Kontrolle der wundvernarbung mit calmodulin-inhibitoren oder protein-kinase-c-inhibitoren
AU8806798A (en) Diphosphonic acid salts for the treatment of osteoporosis
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
PT980253E (pt) Somatostatina e agonistas de somatostatina para tratar a insensibilidade a insulina e a sindrome x
KR950013519A (ko) 골절 예방 및 치료용 약제
ID24561A (id) Pemakaian protein matriks oligomerik kartilaj untuk mengobati artritis rematoid
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]